U.S. Tysabri Labeling Updated With More PML Risk Info But No Reference To JCV Testing
This article was originally published in The Pink Sheet Daily
Executive Summary
Partners Biogen Idec and Elan had asked both European and U.S. regulators to update the label to include the addition of anti-JC virus antibody status as a risk factor, but so far only the EU has moved toward JCV testing.
You may also be interested in...
Tysabri Usage Restrictions Likely To Remain Stable As FDA Considers REMS Modifications
While the label of Biogen Idec/Elan's multiple sclerosis drug is expected to be changed to reflect a suspected link between JC-virus and the viral brain infection progressive multifocal leukoencephalopathy, that is unlikely to lead to a new contraindication.
Tysabri Usage Restrictions Likely To Remain Stable As FDA Considers REMS Modifications
While the label of Biogen Idec/Elan's multiple sclerosis drug is expected to be changed to reflect a suspected link between JC-virus and the viral brain infection progressive multifocal leukoencephalopathy, that is unlikely to lead to a new contraindication.
Biogen's New EVP Commercial Ops Tony Kingsley: An Interview With "The Pink Sheet" DAILY
Execution, discipline, and reliance on proven sales and marketing methods helped turn around key multiple sclerosis drug Avonex, says Biogen's new EVP, Global Commercial Operations.